NYON, Switzerland, September 16 /PRNewswire-FirstCall/ -- Mymetics
Corporation (OTCBB: MYMX), a vaccine development company, is pleased to
announce their preliminary SHIV challenge results on non-human primates
previously immunized with the Company's mucosal HIV-AIDS vaccine designed
for triggering mucosal protection. The results significantly exceed the
Industry standard of 60% to 70% effectiveness to be considered as a
promising vaccine as well as of Mymetics' expectation which was
considerable above this level. The Company will continue to do further
tests to confirm these results and will present the all results at the
Keystone Symposia. With the recent public announcements by major HIV
opinion leaders and pharmaceutical companies of their disappointing results
despite significant investments in non productive vaccine strategies,
attention is now beginning to refocus on the mucosa approach. Mymetics,
with a robust IP portfolio and having originally decided 5 years ago to
develop an HIV vaccine utilising mucosal antibody protection as the first
line of defence, anticipates a fundamental change in the direction of
HIV/AIDS research towards the mucosa solution in the near future.

Mymetics' viral challenge was its second non-human primate study
conducted by the Institute of Laboratory Animal Science & Chinese Academy
of Medical Science (ILAS) in Beijing. ILAS, a globally recognized
analytical facility, have and continue to be used by leading US scientists
and major governmental entities for ongoing scientific testing. This study
used macaques for evaluating Mymetics' latest HIV vaccine formulation and
consisted of three differing methodologies of immunizing the macaques. The
macaques were intra-vaginally challenged thirteen times with the chimeric
SHIV. Female Chinese Macaca Mulata (macaques) were chosen as their
infection by SHIV through the genital route closely resembles the observed
human infection rate by HIV. The company expects to present the fully
detailed results as well as the challenge protocols at the next major
conference on HIV/AIDS at the Keystone Symposia in Colorado in March 2009.

Reaching completion of the toxicology studies on animals, the company
expects to initiate Phase I Human Clinical trials process in November 2008.

"Considering the repeated failures in developing a sustainable AIDS
vaccine as widely reported in the press, we are very excited with the
outstanding preliminary results of our viral challenge using our latest
generation mucosal AIDS vaccine and look forward to a lively discussion on
these results at the Keystone Conference" said Christian J. F. Rochet,
President and CEO of Mymetics Corporation. "Our Chief Scientific Officer,
Dr. Sylvain Fleury will attend the AIDS vaccine conference in South Africa
in October and discuss informally our SHIV/AIDS results with other
participants. We expect to release the complete results as well as the
independent verification of those results at the Keystone Symposia.
According to the WHO, it is estimated that there are over 33 million people
living with HIV with a further 2.5 million new infections in 2007 alone.
There is clearly an urgent need within the global community for an
effective prophylactic AIDS vaccine and our results leave hope that the
development of such a vaccine is not an impossible task."

Since 2004 Mymetics has pursued and furthered a mucosa approach that
focuses on preventing early HIV entry into the human organism during the
first minutes or hours following exposure to the HIV virus. Its success is
based on proprietary know how and key intellectual property in matters of
antigen engineering and vaccine design that has enabled Mymetics to
engineer an effective vaccine candidate in the fight against HIV/AIDS.

About Mymetics Corporation

Mymetics is a biotechnology company developing prophylactic vaccines
that combine innovative antigen engineering, minimal human protein
homologies and virosome technology licensed from Pevion Biotech Ltd.
Mymetics' vaccine approach focuses on eliciting immune protection capable
of interfering with late events of pathogen transmission, a generally
accepted approach coupled, uniquely and most importantly, with early events
of pathogen transmission, such as preventing virus entry across the mucosal
tissues, the primary entry door of most pathogens. Virosomes are lipidic
vesicles derived from influenza virus membrane that are non-replicative
antigen carriers which possess intrinsic systemic and mucosal adjuvant
properties. Virosomes are approved in 42 countries and have been used since
1994 for two vaccines in over 40 million doses with no significant side
effects. The Company's disease focus presently includes malaria and the
human immunodeficiency virus.

Statements contained in this release that are not strictly historical
are "forward-looking statements."Such forward-looking statements are
sometimes identified by words such as
"intends,""anticipates,""believes,""expects" and "hopes."The
forward-looking statements are made based on information available as of
the date hereof, and the Company assumes no obligation to update such
forward-looking statements. Editors and investors are cautioned that such
forward-looking statements involve risks and uncertainties that could cause
the Company's actual results to differ materially from those in these
forward-looking statements. Such risks and uncertainties include but are
not limited to demand for the Company's products and services, our ability
to continue to develop markets, general economic conditions, our ability to
secure additional financing for the Company and other factors that may be
more fully described in reports to shareholders and periodic filings with
the Securities and Exchange Commission.

(Date:12/8/2016)... Research and Markets has announced the addition ... ... The global chromatography market to grow at a CAGR of ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...

(Date:12/8/2016)... TEMPE, Ariz., Dec. 8, 2016 Economic growth in ... nation,s purchasing and supply management executives in their December ... of the economic recovery that began in mid-2009, as ... On Business ® . The manufacturing sector is ... increase in 16 manufacturing industries, and the non-manufacturing sector ...

(Date:12/8/2016)... 8, 2016 Noom, Inc., the leader in ... enterprise customers only when their members achieve real health ... wellness sector, which typically charges for arbitrary enrollment, participation ... The ... technology with the empathy of live human coaches to ...